Heart failure & cardiomyopathies
Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
Authors' conclusion
NT-proBNP increase and ODI can serve as markers of WCD and predict mortality and CV hospitalisations in a cohort of patients taking tafamidis.
Study context
- Population
- Patients diagnosed with ATTR-CM at Columbia University after 2018 who were treated with tafamidispatients enrolled
- Participants
- 238 patients
- Exposure
- Worsening cardiac disease (WCD) at 1 year vs no WCD
- WCDn = 100
- Outcome
- WCD at 1 year
- Follow-up
- 1 year
Main finding
As reported in the abstract
Patients showing WCD at 1 year
100
42%
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| MortalityAdjusted for age, genotype and baseline NAC stage | 1.91 (1.10–3.32) | P = 0.023 | |
| CV-related hospitalisationCompeting risk analysis | 1.8 (1.17–2.99) | P = 0.009 | |
| 0.20.5125Hazard ratio (log scale) |
- Mortality: after adjustment for age, genotype and baseline National Amyloidosis Centre (NAC) stage; log rank, p<0.0001
- Cardiovascular (CV)-related hospitalisation: competing risk analysis, adjusted for age, genotype and baseline NAC stage
Original publication
Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Heart. Published 23 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →